Mhd Monzr Al Malki, MD
Hematology · Duarte, CANPI 1043489362
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,315 of the $46,054 with a category attached, or 78.9%. 18 manufacturers reported payments, led by Gamida Cell Inc. at 25.1% of the total. 2025 is the largest year on record at $25,642, 4.6 times the $5,555 reported in 2019.
Across 61 payments — averaging $754.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gamida Cell Inc.$12K
- Incyte Corporation$8K
- Jazz Pharmaceuticals Inc.$7K
- Medexus Pharma, Inc.$5K
- Sobi, Inc$3K
- Stemline Therapeutics Inc.$3K
- plus $9K from 12 others
Across 63 payments — averaging $29,943 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- National Marrow Donor Program$932K
- Takeda Pharmaceuticals U.S.A., Inc.$424K
- Incyte Corporation$312K
- Genentech, Inc.$120K
- Gilead$73K
- Sanofi US Services Inc.$25K
What the payments were for
- Consulting fees$36,31579%
- Speaking & faculty fees$2,6006%
- Travel & lodging$5,40212%
- Food & beverage$1,7384%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gamida Cell Inc. | 5 | $11,560 |
| Incyte Corporation | 20 | $8,431 |
| Jazz Pharmaceuticals Inc. | 4 | $6,539 |
| Medexus Pharma, Inc. | 2 | $4,760 |
| Sobi, Inc | 3 | $2,833 |
| Stemline Therapeutics Inc. | 3 | $2,718 |
| Gilead | 3 | $2,400 |
| National Marrow Donor Program | 2 | $2,247 |
| Taiho Oncology, Inc. | 2 | $2,125 |
| Genentech USA, Inc. | 3 | $1,882 |
| AstraZeneca | 5 | $118 |
| E.r. Squibb & Sons, L.L.C. | 1 | $117 |
| Pfizer | 1 | $113 |
| Rigel Pharmaceuticals, Inc. | 1 | $61 |
| Novartis | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Bristol Myers Squibb | 1 | $24 |
| AbbVie | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,054 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 12 | $157 |
| Carvedilol | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.